Earnings Call Summary | Evoke Pharma(EVOK.US) Q4 2023 Earnings Conference
Earnings Call Summary | Evoke Pharma(EVOK.US) Q4 2023 Earnings Conference
The following is a summary of the Evoke Pharma, Inc. (EVOK) Q4 2023 Earnings Call Transcript:
以下是Evoke Pharma, Inc.（EVOK）2023年第四季度業績電話會議記錄摘要：
Financial Performance:
財務業績：
Evoke Pharma reported net revenue for GIMOTI doubled over the last year.
New prescriptions grew by 86% and total prescriptions dispensed increased by 101% year-over-year.
The company forecasts a net revenue of approximately $14 million for 2024, nearly tripling its performance in 2023.
Q4 net product sales were roughly $1.7 million, a noteworthy increase from $796,000 in Q4 of 2022.
The company's net loss for Q4 was $2 million or $0.59 per share, compared to $1.8 million or $0.54 per share in the corresponding period of the previous year.
For the full year 2023, net product sales were about $5.2 million, compared to around $2.5 million in 2022.
Operating expenses for 2023 totaled around $12.6 million, up from about $10.3 million in 2022, primarily due to higher marketing royalty and Eversana profit sharing costs.
Evoke Pharma報告稱，GIMOTI的淨收入比去年翻了一番。
新處方藥同比增長了86％，發放的處方總量同比增長了101％。
該公司預計，2024年的淨收入約爲1400萬美元，將近2023年的業績增長了三倍。
第四季度產品淨銷售額約爲170萬美元，較2022年第四季度的79.6萬美元顯著增長。
該公司第四季度的淨虧損爲200萬美元，合每股虧損0.59美元，而去年同期爲180萬美元，合每股虧損0.54美元。
2023年全年，產品淨銷售額約爲520萬美元，而2022年約爲250萬美元。
2023年的運營支出總額約爲1,260萬美元，高於2022年的約1,030萬美元，這主要是由於更高的營銷特許權使用費和Eversana的利潤分享成本。
Business Progress:
業務進展：
Evoke Pharma expanded its prescriber base by 72% and deepened their prescribing by 36%.
The company has reported positive patient experiences related to GIMOTI.
Evoke Pharma transitioned its pharmacy services to ASPN to meet its distribution needs better, enhance patient access, and streamline services.
The company doubled the patient count on GIMOTI therapy in 2023 and anticipates further growth in 2024.
Evoke Pharma started partnering with ASPN Pharmacy to access a wider pharmacy network and improve GIMOTI fill rates.
Through increased communication and education about tardive dyskinesia, Evoke Pharma aims to shift the narrative from fear to informed prescribing.
They plan to invest in patient and provider education, aiming to shift the narrative around tardive dyskinesia and promote informed prescribing.
They have evolved their distribution and pharmacy capabilities; from implementing EvokeAssist, upgrading to VidaCare, to partnering with Asembia; enabling them to scale their reach further.
Growth has been driven by relationships with ASPN Pharmacy and high real-world data comparing GIMOTI to oral metoclopramide.
The company is monitoring the potential impact on its business from the situation with Change Healthcare.
Evoke Pharma is exploring a possible correlation between the use of GLP-1 agonists and the increase in the number of people suffering from gastroparesis, anticipating a potential market opportunity if a link is confirmed.
Evoke Pharma將其處方藥基礎擴大了72％，並將處方深化了36％。
該公司報告了與GIMOTI相關的積極患者體驗。
Evoke Pharma將其藥房服務過渡到ASPN，以更好地滿足其分銷需求，增加患者可及性並簡化服務。
該公司在2023年將GIMOTI療法的患者人數翻了一番，並預計在2024年將進一步增長。
Evoke Pharma開始與ASPN Pharmacy合作，以接入更廣泛的藥房網絡並提高GIMOTI的填充率。
通過加強有關遲發性運動障礙的溝通和教育，Evoke Pharma旨在將敘事從恐懼轉向明智的處方。
他們計劃投資於患者和醫療服務提供者教育，旨在改變圍繞遲發性運動障礙的說法，促進明智處方。
他們已經發展了自己的分銷和藥房能力；從實施EvokeAssist、升級到VidaCare到與Asembia合作；使他們能夠進一步擴大覆蓋範圍。
與ASPN Pharmacy的關係以及將GIMOTI與口服甲氧氯普胺進行比較的大量真實數據推動了增長。
該公司正在監測Change Healthcare的情況對其業務的潛在影響。
Evoke Pharma 正在探索 GLP-1 激動劑的使用與胃輕癱患者人數增加之間可能存在的相關性，預計如果這種聯繫得到證實，將出現潛在的市場機會。
More details: Evoke Pharma IR
更多詳情： Evoke Pharma IR
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。
譯文內容由第三人軟體翻譯。